Endocrinology · Medical Literature
Autoimmune Thyroid Diseases After COVID-19 Infection: A Systematic Review of Clinical Manifestation and Outcomes.
Abstract
Background: Increasing evidence suggests that COVID-19 can induce or exacerbate autoimmune disorders, including immune-mediated thyroid dysfunction. The most common autoimmune thyroid diseases are Graves' disease and Hashimoto's thyroiditis; the mechanisms by which viral infections like SARS-CoV-2 trigger these diseases are not fully understood. Objectives: This study aims to systematically review published clinical evidence on the presentation, laboratory characteristics, and outcomes of autoimmune thyroid diseases after COVID-19 infection. Methods: The review followed the PRISMA 2020 framework. Scopus, Web of Science, and PubMed were searched for English-language studies between January 2020 and December 2025 using the terms COVID-19, SARS-CoV-2, autoimmune thyroiditis, Graves' disease, Hashimoto's thyroiditis, and autoimmune thyroid disease. Results: In total, 46 studies (five cohort studies and 41 case reports/series) involving 3856 patients were analyzed. The findings indicate that a significant increase in TPOAb prevalence occurs post-COVID-19 infection (15.7% vs. 7.7% in controls). New-onset Graves' disease (GD) post-COVID-19 presented with higher fT3/fT4 ratios and more aggressive thyrotoxicosis compared to non-viral cases. Rare but severe manifestations included thyrotoxic periodic paralysis, Hashimoto's encephalopathy, and dilated cardiomyopathy. Conclusions: SARS-CoV-2 may act as a trigger for autoimmune thyroid diseases, particularly in moderate-to-severe infections; however, the strength of this association warrants further investigation with controlled prospective data. Standard therapy remains effective, but thyroid function monitoring is advisable during post-COVID-19 recovery. An interdisciplinary approach is essential for early diagnosis and management of systemic complications.
Clinical relevance
What are the clinical presentations, laboratory characteristics, and outcomes of autoimmune thyroid diseases (Graves' disease and Hashimoto's thyroiditis) that develop or are exacerbated following COVID-19 infection? __SNAPSHOT__ {"studyDesign":"Systematic review of cohort studies, case reports, and case series following PRISMA 2020 framework; no meta-analysis reported","setting":"International; Scopus, Web of Science, and PubMed searched for English-language publications, January 2020–December 2025; authors affiliated with Semey Medical University and West Kazakhstan Marat Ospanov Medical University, Kazakhstan","sampleSize":"n = 3,856 patients across 46 studies (5 cohort studies, 41 case reports/series)","population":"Adults (≥18 years) with laboratory-confirmed SARS-CoV-2 infection (PCR or serology) who developed new-onset or exacerbated autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease, or mixed forms), diagnosed by positive thyroid autoantibodies (TPOAb, TgAb, TRAb, or TSI), characteristic imaging, or typical biochemical patterns","intervention":"SARS-CoV-2 infection (natural infection as exposure); not an interventional study","comparator":"Control populations reported within individual cohort studies (e.g., one prospective cohort of 599 COVID-19 survivors vs. 498 pre-pandemic controls for TPOAb prevalence; multicenter case–control data for Graves' disease phenotyping); no unified comparator across all 46 studies","primaryOutcome":"Clinical presentation, laboratory characteristics, and clinical outcomes of autoimmune thyroid diseases occurring after COVID-19 infection; no single pre-specified primary endpoint defined across all included studies","followUp":"Variable by study; one cited cohort used 6-month follow-up for antibody levels; overall duration not uniformly reported across the review","fundingSource":"Not reported in the available abstract or indexed article metadata"}
Key findings
The review synthesized data from 46 studies (n = 3,856). The most quantitatively robust autoimmunity signal came from a prospective cohort of 599 COVID-19 survivors in which TPOAb prevalence was approximately double that of controls (15.7% vs. 7.7%; p-value reported in the source cohort as 0.002, not independently reported in this systematic review's summary). A separate large retrospective cohort (n = 2,339) confirmed elevated TPOAb and TgAb levels during a 6-month follow-up, with antibody levels correlating with initial COVID-19 severity. A key qualitative differentiator was identified in a multicenter case–control study: patients with new-onset Graves' disease following SARS-CoV-2 presented with significantly higher fT3 levels and higher fT3/fT4 ratios compared to non-viral Graves' disease cases, suggesting a more intense thyrotoxic state. Specific fT3 and fT4 values, confidence intervals, odds ratios, NNT, and NNH were not reported in the available abstract. Adverse outcomes described in the case report literature included thyrotoxic crisis, Graves' ophthalmopathy, and at least one death attributable to myxedema coma. The review did not perform pooled statistical synthesis (meta-analysis); all effect estimates derive from individual included studies.
Practice implications
This systematic review establishes that new-onset or exacerbated autoimmune thyroid diseases—principally Graves' disease and Hashimoto's thyroiditis—are documented sequelae of SARS-CoV-2 infection across a broad international case literature. The most clinically salient finding is that post-COVID-19 Graves' disease may present with a phenotypically more severe thyrotoxic profile (higher fT3/fT4 ratio) than classic non-viral Graves' disease, which has implications for initial antithyroid drug dosing and monitoring intensity. The finding of roughly doubled TPOAb prevalence in COVID-19 survivors compared to controls is biologically plausible given SARS-CoV-2-mediated immune dysregulation and ACE2 receptor expression on thyrocytes. However, the review does NOT establish causality, does not determine incidence rates of frank clinical disease (as opposed to antibody positivity), and does not identify which COVID-19 survivors will progress from autoantibody positivity to overt thyroid dysfunction. The evidence base is heavily dominated by case reports and series (41 of 46 studies), which are subject to publication bias toward dramatic or novel presentations. Findings are most applicable to adults; children and immunocompromised populations were not adequately represented. The abstract was truncated and the full conclusions section was not available for review, which limits complete characterization of the authors' stated conclusions. This summary is based on the abstract and indexed article content only. __LIMITATIONS__ Severe study design heterogeneity: 41 of 46 included studies are case reports or series, which are highly susceptible to publication bias and do not permit reliable prevalence or incidence estimation.,No meta-analysis performed; pooled effect sizes, confidence intervals, and heterogeneity statistics are not reported, preventing quantitative synthesis of risk.,Causality cannot be established from observational and case data alone; confounding by pre-existing subclinical autoimmunity, genetic susceptibility, concomitant medication use (e.g., steroids, remdesivir), or non-thyroidal illness syndrome affecting thyroid indices is not systematically addressed.,Autoantibody positivity was not a mandatory inclusion criterion for individual studies, introducing diagnostic heterogeneity and potential misclassification of subacute (de Quervain) thyroiditis as autoimmune thyroid disease.,Follow-up duration varies substantially across included studies, making it impossible to determine long-term resolution rates, persistence of autoimmunity, or risk of hypothyroidism development from this review alone.,The comparator groups differ significantly between included cohorts (pre-pandemic controls, non-viral Graves' disease, unexposed contemporaneous controls), limiting cross-study comparisons.,Predominance of female patients in the case literature reflects known sex predisposition for autoimmune thyroid disease but may over-represent this group relative to the broader post-COVID population.,Funding source not reported; potential conflicts of interest cannot be assessed.,Abstract was truncated in the source material, precluding complete assessment of the authors' conclusions, subgroup analyses, and discussion of limitations as stated by the authors themselves. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This PRISMA-compliant systematic review of 46 studies (n = 3,856) provides the most comprehensive synthesis to date of autoimmune thyroid disease following COVID-19, demonstrating approximately doubled TPOAb prevalence in survivors versus controls and a phenotypically more aggressive thyrotoxic presentation in post-COVID Graves' disease. Clinicians should maintain a low threshold to assess thyroid function and autoantibodies in symptomatic post-COVID patients, recognizing that new-onset Graves' disease in this context may require more intensive antithyroid therapy than classic presentations. Definitive incidence estimates, causal inference, and long-term outcome data await prospective controlled studies with standardized diagnostic criteria and uniform follow-up.